GSK 2831781

Drug Profile

GSK 2831781

Alternative Names: GSK2831781; ImmuTune-IMP731; IMP-731

Latest Information Update: 21 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immutep
  • Developer GlaxoSmithKline
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 29 Mar 2018 Immutep announces intention to launch GSK 2831781 (IMP 731) for Autoimmune diseases in 2023
  • 07 Mar 2018 GlaxoSmithKline completes a phase I trial in Plaque psoriasis in Germany and United Kingdom (IV) (NCT02195349)
  • 06 Feb 2018 GSK 2831781 is still in phase I trials for Plaque psoriasis in Germany and United Kingdom (GlaxoSmithKline pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top